{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:50:37Z","timestamp":1790859037319,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ejca.2023.113495","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T20:10:12Z","timestamp":1702671012000},"page":"113495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Immunotherapy in mismatch repair-deficient metastatic colorectal cancer \u2013 Outcome and novel predictive markers"],"prefix":"10.1016","volume":"198","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2357-3923","authenticated-orcid":false,"given":"Amos","family":"Stemmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0319-9038","authenticated-orcid":false,"given":"Ofer","family":"Margalit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Serpas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gal","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preksha","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0849-1708","authenticated-orcid":false,"given":"Noam","family":"Tau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keren","family":"Levanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einat","family":"Shacham-Shmueli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Kopetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Overman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1304-8340","authenticated-orcid":false,"given":"Ben","family":"Boursi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejca.2023.113495_bib1","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.bjc.6604867","article-title":"Deficient mismatch repair system in patients with sporadic advanced colorectal cancer","volume":"100","author":"Koopman","year":"2009","journal-title":"Br J Cancer"},{"issue":"15","key":"10.1016\/j.ejca.2023.113495_bib2","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/jama.2012.13088","article-title":"Identification of lynch syndrome among patients with colorectal cancer","volume":"308","author":"Moreira","year":"2012","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.ejca.2023.113495_bib3","doi-asserted-by":"crossref","DOI":"10.1200\/PO.22.00179","article-title":"The prevalence and prognosis of microsatellite instability-high\/mismatch repair-deficient colorectal adenocarcinomas in the United States","volume":"7","author":"Gutierrez","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"23","key":"10.1016\/j.ejca.2023.113495_bib4","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"New Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2023.113495_bib5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1200\/JCO.21.01015","article-title":"First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II checkMate 142 study","volume":"40","author":"Lenz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2023.113495_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.19.02107","article-title":"Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164","volume":"38","author":"Le","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2023.113495_bib7","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2023.113495_bib8","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.annonc.2022.06.008","article-title":"Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142","volume":"33","author":"Andr\u00e9","year":"2022","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2023.113495_bib9","unstructured":"Calcagno V. Model Selection and Multimodel Inference Made Easy [R package glmulti version 1.0.8]. Published online May 26, 2020. Accessed May 7, 2023. https:\/\/cran.r-project.org\/package=glmulti."},{"issue":"1","key":"10.1016\/j.ejca.2023.113495_bib10","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-6073-7","article-title":"Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy","volume":"19","author":"Bilen","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2023.113495_bib11","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejca.2022.08.034","article-title":"High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy","volume":"177","author":"Dercle","year":"2022","journal-title":"Eur J Cancer"},{"issue":"52","key":"10.1016\/j.ejca.2023.113495_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aba0759","article-title":"Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis","volume":"5","author":"Lee","year":"2020","journal-title":"Sci Immunol"},{"issue":"1","key":"10.1016\/j.ejca.2023.113495_bib13","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2023.113495_bib14","doi-asserted-by":"crossref","first-page":"S684","DOI":"10.1016\/j.annonc.2022.07.458","article-title":"A phase I clinical trial of regorafenib, ipilimumab, and nivolumab (RIN) in chemotherapy resistant MSS metastatic colorectal cancer (mCRC)","volume":"33","author":"Fakih","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.113495_bib15","doi-asserted-by":"crossref","first-page":"S376","DOI":"10.1016\/j.annonc.2022.04.453","article-title":"LBA O-9 Botensilimab, a novel innate\/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer","volume":"33","author":"Bullock","year":"2022","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2023.113495_bib16","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.0400","article-title":"Association between survival and metastatic site in mismatch repair-deficient metastatic colorectal cancer treated with first-line pembrolizumab","volume":"6","author":"Saberzadeh-Ardestani","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1016\/j.ejca.2023.113495_bib17","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1001\/jamaoncol.2021.4971","article-title":"Uptake and survival outcomes following immune checkpoint inhibitor therapy among trial-ineligible patients with advanced solid cancers","volume":"7","author":"Parikh","year":"2021","journal-title":"JAMA Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923007979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923007979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T20:34:54Z","timestamp":1721680494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923007979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":17,"alternative-id":["S0959804923007979"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113495","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy in mismatch repair-deficient metastatic colorectal cancer \u2013 Outcome and novel predictive markers","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113495","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113495"}}